1[2]Wang YX,da Cunha V,Vincelette J,et al.Antiviral and myocyte protective effects of murine interferon-beta and-{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice.Am J Physiol Heart Circ Physiol JT-American journal of physiology.Heart and circulatory physiology,2007,293(1):69-76.
2[3]Liu PP,Mason JW.Advances in the understanding of myocarditis.Circulation JT-Circulation,2001,104(9):1076-82.
3陈慰峰，金伯全．医学免疫学[M]．4版．北京：人民卫生出版社，2004：208—220．
4Kashimura T, Kodama M, Hotta Y, et al. Spatiotemporal changes of coxsackievirus and adenovirus receptor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat[ J]. Virchows Arch ,2003,444 ( 3 ) :283-292.
5Carson SD. Receptor for the group B coxsackieviruses and adenoviruses :CAR[J]. Rev Med Virol,2001,11 (4) :219-226.
6Schmidtke M,Selinka HC, Heim A, et al. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic difference to capsid protein VP1 [ J ]. J Virol, 2000, 275 ( 1 ) : 77-88.
7Huber SA,Graveline D, Newell MK, et al. cells Vγ1^+ T suppress and Vγ4^+ cell promote susceptibility to coxsackievirus B3-induced myocarditis in mice[ J ]. J Immunol,2000,165 (6) :4174-4181.
8Zlotnic A, Yoshie O. Chemokines:a new classification system and their role in immunity[ J]. Immunity,2000,12 (10) : 121-126.
8Yun SH, Lee WG, Kim YC, et al. Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis[J] J Infect Dis, 2012,205 (3) : 491- 497.
9Mohite PN, Popov AF,Bartsch A. Successful treatment of novel H1N1 influenzarelated fulminant myocarditis with extracorporeal life support[J]. J Cardiothorac Surg,2011, 20(6) :164-172.
10Burke JD,Sonenberg N, Platanias LC. Antiviral effects of interferon-： are enhanced in the absence of the transla- tional suppressor 4E-BP1 in myocarditis induced by cox- sackievirus B3[J]. Antivir Ther, 2011,16 (4) .. 577-584.
